HCRU and Treatment Pathways in Advanced Melanoma
Research type
Research Study
Full title
OPtIMUm study - Observational Study of Practice Patterns and Resource Use among Advanced Melanoma Patients using the Linked Public Health England Cancer Datasets
IRAS ID
269362
Contact name
Adrian Paul Rabe
Contact email
Sponsor organisation
Merck Sharp & Dohme Corp.
Duration of Study in the UK
0 years, 5 months, 31 days
Research summary
Melanoma is a cancer of the cells that produce skin colour. Individuals whose melanoma has reached a certain size or spread to other parts of the body are considered to have advanced melanoma. Being a very debilitating disease, it is important to understand how much resources they use up in the national health service, as well as the various treatments they undergo, and how those treatments impact their survival. This study aims to use anonymized and pseudonymized data from Public Health England to construct a group of patients with advanced melanoma. Using the same dataset linked to secondary care and to the cancer treatment dataset, the study would determine survival, healthcare resource use and treatment pathways. The span of time covered would be from 2015 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reduce healthcare resources and reconfigure services to provide better treatment pathways for patients.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
19/NW/0492
Date of REC Opinion
2 Aug 2019
REC opinion
Favourable Opinion